MDL 19205 demonstrates potent, direct-acting cardiotonic properties, improving cardiac contractile force and reversing induced heart failure in canine models.
No takes yet. Share an insight, caveat, or question.
Preclinical reversal of induced heart failure supports further development of MDL 19205; leaves open translation to human therapy.
Dage et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: